<DOC>
	<DOCNO>NCT01198301</DOCNO>
	<brief_summary>The investigator want develop gene expression profile prediction chemotherapeutic response patient metastatic breast cancer .</brief_summary>
	<brief_title>Gene Expression Profiling Metastatic Breast Cancer Predict Therapeutic Response Chemotherapy</brief_title>
	<detailed_description>1 . Metastatic breast cancer tissue obtain core needle biopsy pretreatment flash frozen store -70℃ processing . 2 . After patient receive docetaxel combination thiotepa two cycle , response assess use Response Evaluation Criteria Solid Tumor Group ( RECIST ) guideline . Degree response use divide cancer two groups—sensitive resistant tumour . 3 . The gene expression metastatic breast cancer tissue sample detect microarray screen gene marker differently express group 4 . Statistical analysis perform use unsupervised hierarchical cluster .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Patients histologically confirm metastatic breast cancer ; Patients complete planned chemotherapy regimen major protocol violation ; Eastern Cooperative Oncology Group ( ECOG ) performance status 02 ; At least one measurable lesion ; Normal cardiac , hepatic , renal bone marrow function ; Life expectancy ≥3 month ; Discontinuity previous chemotherapy minimum 4 week . previous history malignancy ; previous surgery history needle biopsy organ ; Central nervous system metastasis ; Serious uncontrolled concurrent medical illness .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Metastatic Breast Neoplasms</keyword>
	<keyword>Gene Expression Profiling</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>